{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T05:00:38Z","timestamp":1789448438054,"version":"build-2803163510"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T00:00:00Z","timestamp":1749427200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The management of moderate-to-severe psoriasis in patients with concurrent or previous malignancy presents a unique clinical challenge. Despite the transformative impact of biologic therapies on psoriasis treatment, the exclusion of patients with malignancy from clinical trials has led to a paucity of data regarding the safety and efficacy of systemic and biologic agents in this subgroup. Clinicians are thus often compelled to rely on registry data, real-world evidence and expert opinion when navigating these complex cases.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To investigate prescribing practices among psoriasis experts for systemic and biologic therapies in patients with severe psoriasis and concomitant malignancy. The study aimed to elucidate trends in decision making, perceptions of treatment risks and adherence to multidisciplinary approaches.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>An electronic survey was disseminated to 141 members of the International Psoriasis Council (IPC) between December 2023 and June 2024. The self-administered questionnaire examined respondents\u2019 demographics, guideline familiarity and preferences for systemic and biologic therapies across five malignancy types (breast cancer, melanoma, prostate cancer, lymphoma and metastatic renal cell carcinoma) at varying remission intervals. Data were analysed descriptively.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Fifty-seven IPC councillors completed the survey (40%). Anti-interleukin-17 agents were the most commonly selected therapies across all malignancy scenarios for patients in remission, reflecting growing confidence in their safety profiles. For active malignancies, apremilast was the most frequently chosen agent, particularly for breast cancer (61%), melanoma (56%) and metastatic renal cell carcinoma (49%). Tumour necrosis factor-\u03b1 inhibitors and fumaric acid esters were the least frequently selected treatments for active malignancies. The majority of respondents (70%) believed current guidelines lacked clarity on treating psoriasis in the context of malignancy. Nearly half (49%) reported always consulting oncology teams before initiating systemic therapy for patients with recent malignancy diagnoses, underscoring the importance of a multidisciplinary approach.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>This study highlights significant variability in prescribing practices and a strong preference for biologics such as anti-IL-17 agents and apremilast. The findings underscore the urgent need for malignancy-specific guidelines informed by robust long-term safety data to support optimal decision making and improve patient outcomes.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ced\/llaf198","type":"journal-article","created":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T07:46:53Z","timestamp":1746690413000},"page":"1818-1826","source":"Crossref","is-referenced-by-count":2,"title":["Prescribing practices among psoriasis experts for patients with concomitant malignancy: a survey of International Psoriasis Council members"],"prefix":"10.1093","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4958-820X","authenticated-orcid":false,"given":"Stephanie","family":"Bowe","sequence":"first","affiliation":[{"name":"South Infirmary Victoria University Hospital , Cork ,","place":["Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Murphy","sequence":"additional","affiliation":[{"name":"South Infirmary Victoria University Hospital , Cork ,","place":["Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Bourke","sequence":"additional","affiliation":[{"name":"South Infirmary Victoria University Hospital , Cork ,","place":["Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitriona","family":"Ryan","sequence":"additional","affiliation":[{"name":"Institute of Dermatologists , Dublin ,","place":["Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,6,9]]},"reference":[{"key":"2025082212472513700_llaf198-B1","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.jaad.2023.03.035","article-title":"Malignancy rates through 5\u2005years of follow-up in patients with moderate-to-severe psoriasis treated with guselkumab: pooled results from the VOYAGE 1 and VOYAGE 2 trials","volume":"89","author":"Blauvelt","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"2025082212472513700_llaf198-B2","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jdcr.2023.07.007","article-title":"A retrospective review of the management of patients following a malignancy diagnosis on biologic therapies for the treatment of dermatological disorders","volume":"39","author":"Finnegan","year":"2023","journal-title":"JAAD Case Rep"},{"key":"2025082212472513700_llaf198-B3","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/jdv.12106","article-title":"Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies","volume":"28","author":"Mattei","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025082212472513700_llaf198-B4"},{"key":"2025082212472513700_llaf198-B5","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/j.jaad.2020.02.044","article-title":"Joint American Academy of Dermatology\u2013National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies","volume":"82","author":"Menter","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"2025082212472513700_llaf198-B6","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/jdv.16926","article-title":"EuroGuiDerm guideline on the systemic treatment of psoriasis vulgaris \u2013 part 2: specific clinical and comorbid situations","volume":"35","author":"Nast","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025082212472513700_llaf198-B7","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.jaad.2018.11.057","article-title":"Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics","volume":"80","author":"Menter","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"2025082212472513700_llaf198-B8","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1111\/bjd.15665","article-title":"British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017","volume":"177","author":"Smith","year":"2017","journal-title":"Br J Dermatol"},{"key":"2025082212472513700_llaf198-B9","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1111\/bjd.16715","article-title":"Cumulative exposure to biological therapy and risk of cancer in patients with psoriasis: a meta-analysis of Psonet studies from Israel, Italy, Spain, the U.K. and Republic of Ireland","volume":"179","author":"Garcia-Doval","year":"2018","journal-title":"Br J Dermatol"},{"key":"2025082212472513700_llaf198-B10","first-page":"1441","article-title":"Safety observations in 12095 patients with psoriasis enrolled in an international registry (PSOLAR): experience with infliximab and other systemic and biologic therapies","volume":"13","author":"Gottlieb","year":"2014","journal-title":"J Drugs Dermatol"},{"key":"2025082212472513700_llaf198-B11","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1111\/jdv.15448","article-title":"Fumaric acid ester-\u00adinduced T-cell lymphopenia in the real-life treatment of psoriasis","volume":"33","author":"Dickel","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025082212472513700_llaf198-B12","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1046\/j.1365-2133.2003.05433.x","article-title":"Long-term safety aspects of systemic therapy with fumaric acid esters in severe psoriasis","volume":"149","author":"Hoefnagel","year":"2003","journal-title":"Br J Dermatol"},{"key":"2025082212472513700_llaf198-B13","first-page":"4516","article-title":"Essential role of tumor necrosis factor alpha (TNF-\u03b1) in tumor promotion as revealed by TNF-\u03b1-deficient mice","volume":"59","author":"Suganuma","year":"1999","journal-title":"Cancer Res"},{"key":"2025082212472513700_llaf198-B14","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/bjd.15830","article-title":"Risk of cancer in patients with psoriasis on biological therapies: a systematic review","volume":"178","author":"Peleva","year":"2018","journal-title":"Br J Dermatol"},{"key":"2025082212472513700_llaf198-B15","doi-asserted-by":"crossref","first-page":"4542","DOI":"10.1200\/JCO.2007.11.2136","article-title":"Tumor necrosis factor alpha as a new target for renal cell carcinoma: two sequential phase II trials of infliximab at standard and high dose","volume":"25","author":"Harrison","year":"2007","journal-title":"J Clin Oncol"},{"key":"2025082212472513700_llaf198-B16","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1001\/jamadermatol.2020.1300","article-title":"Melanoma risk in patients treated with biologic therapy for common inflammatory diseases: a systematic review and meta-analysis","volume":"156","author":"Esse","year":"2020","journal-title":"JAMA Dermatol"},{"key":"2025082212472513700_llaf198-B17","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1136\/annrheumdis-2016-209270","article-title":"Cancer risk in patients with spondyloarthritis treated with TNF inhibitors: a collaborative study from the ARTIS and DANBIO registers","volume":"76","author":"Hellgren","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2025082212472513700_llaf198-B18","doi-asserted-by":"crossref","first-page":"f1939","DOI":"10.1136\/bmj.f1939","article-title":"Rheumatoid arthritis, anti-tumour necrosis factor therapy, and risk of malignant melanoma: nationwide population based prospective cohort study from Sweden","volume":"346","author":"Raaschou","year":"2013","journal-title":"BMJ"},{"key":"2025082212472513700_llaf198-B19","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/nature14282","article-title":"IL-17-producing \u03b3\u03b4 T cells and neutrophils conspire to promote breast cancer metastasis","volume":"522","author":"Coffelt","year":"2015","journal-title":"Nature"},{"key":"2025082212472513700_llaf198-B20","doi-asserted-by":"crossref","first-page":"110757","DOI":"10.1016\/j.intimp.2023.110757","article-title":"IL-17A functions and the therapeutic use of IL-17A and IL-17RA targeted antibodies for cancer treatment","volume":"123","author":"Song","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"2025082212472513700_llaf198-B21","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/jdv.19520","article-title":"Are interleukin 17 and interleukin 23 inhibitors associated with malignancies? Insights from an international population-based study","volume":"38","author":"Kridin","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025082212472513700_llaf198-B22","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.jaad.2017.07.013","article-title":"Risk of malignancy with systemic psoriasis treatment in the Psoriasis Longitudinal Assessment Registry","volume":"77","author":"Fiorentino","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"2025082212472513700_llaf198-B23","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s40257-023-00783-7","article-title":"Apremilast long-term safety up to 5\u2005years from 15 pooled randomized, placebo-controlled studies of psoriasis, psoriatic arthritis, and Beh\u00e7et\u2019s syndrome","volume":"24","author":"Mease","year":"2023","journal-title":"Am J Clin Dermatol"},{"key":"2025082212472513700_llaf198-B24","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1517\/14656566.2015.1076794","article-title":"Apremilast for the treatment of psoriasis","volume":"16","author":"Chimenti","year":"2015","journal-title":"Expert Opin Pharmacother"},{"key":"2025082212472513700_llaf198-B25","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1016\/j.cellsig.2014.05.014","article-title":"Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity","volume":"26","author":"Schafer","year":"2014","journal-title":"Cell Signal"},{"key":"2025082212472513700_llaf198-B26","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1038\/s41416-023-02172-7","article-title":"Use of methotrexate and risk of skin cancer: a nationwide case\u2013control study","volume":"128","author":"Polesie","year":"2023","journal-title":"Br J Cancer"},{"key":"2025082212472513700_llaf198-B27","first-page":"e37174","article-title":"Psoriasis patients treated with methotrexate have an increased risk of nonmelanoma skin cancer: a systematic review and meta-analysis","volume":"15","author":"Lang Houser","year":"2023","journal-title":"Cureus"},{"key":"2025082212472513700_llaf198-B28","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1001\/jamadermatol.2022.3337","article-title":"Association between low-dose methotrexate exposure and melanoma: a systematic review and meta-analysis","volume":"158","author":"Yan","year":"2022","journal-title":"JAMA Dermatol"},{"key":"2025082212472513700_llaf198-B29","doi-asserted-by":"crossref","first-page":"3713","DOI":"10.3390\/jcm13133713","article-title":"Basic susceptibility of patients with psoriasis under systemic therapy for respiratory infections: data from the German psoriasis registry PsoBest","volume":"13","author":"Stephan","year":"2024","journal-title":"J Clin Med"},{"key":"2025082212472513700_llaf198-B30","doi-asserted-by":"crossref","first-page":"T702","DOI":"10.1016\/j.ad.2024.05.011","article-title":"[Translated article] Recommendations from the Spanish Academy of Dermatology and Venereology Psoriasis Working Group on the Management of Patients with Cancer and Psoriasis","volume":"115","author":"Puig","year":"2024","journal-title":"Actas Dermosifiliogr"},{"key":"2025082212472513700_llaf198-B31","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1111\/bjd.19039","article-title":"British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020: a rapid update","volume":"183","author":"Smith","year":"2020","journal-title":"Br J Dermatol"},{"key":"2025082212472513700_llaf198-B32","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1053\/j.gastro.2016.03.037","article-title":"Cancer recurrence following immune-suppressive therapies in patients with immune-mediated diseases: a systematic review and meta-analysis","volume":"151","author":"Shelton","year":"2016","journal-title":"Gastroenterology"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llaf198\/63241105\/llaf198.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/50\/9\/1818\/63241105\/llaf198.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/50\/9\/1818\/63241105\/llaf198.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T16:47:37Z","timestamp":1755881257000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/50\/9\/1818\/8138102"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,9]]},"references-count":32,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,6,9]]},"published-print":{"date-parts":[[2025,8,22]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llaf198","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"value":"0307-6938","type":"print"},{"value":"1365-2230","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,9]]},"published":{"date-parts":[[2025,6,9]]}}}